SCHEMBL148467

SCHEMBL148467

NC(=O)c1c(-c2cccnc2)ccc2c1[nH]c1ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.54
PIM1 P11309 1/20 0.46
PIM3 Q86V86 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
MKNK1 Q9BUB5 2/20 0.46
MKNK2 Q9HBH9 2/20 0.46
PARP14 Q460N5 1/20 0.45
PARP1 P09874 1/20 0.45
DHODH Q02127 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
PKN1 Q16512 1/20 0.44
PKN2 Q16513 1/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7723752 0.89 PIM3 (0.47) TDO2PIM1PIM3PARP14PKN1
SCHEMBL28301583 0.80 TDO2 (0.60) TDO2PIM1CYP11B1CYP11B2PARP14
SCHEMBL29572015 0.78 TDO2 (0.65) TDO2PIM1CYP11B1CYP11B2PARP14
SCHEMBL148203 0.78 TDO2 (0.65) TDO2PIM1CYP11B1CYP11B2PARP14
SCHEMBL148605 0.78 PIM1 (0.44) PIM1PIM3PARP14BTK
SCHEMBL149085 0.77 BCHE (0.46) PIM1PIM3PARP14PARP1CDK4
SCHEMBL148354 0.77 PIM1 (0.45) TDO2PIM1PIM3PARP14BTK
SCHEMBL27997778 0.77 JAK2 (0.59) TDO2MKNK1MKNK2PARP1DHODH
SCHEMBL147833 0.76 PIM3 (0.50) PIM1PIM3PARP14PARP1TUBB4A
SCHEMBL28301576 0.75 TDO2 (0.58) TDO2PIM1CYP11B1CYP11B2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TDO2 2235/4885PIM1 90/4885PIM3 102/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TDO2 2235/4885PIM1 90/4885PIM3 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.